APA (7th ed.) Citation

Yan Li, Xueyan Liang, Huijuan Li, Tong Yang, Sitong Guo, & Xiaoyu Chen. (2022). Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Yan Li, Xueyan Liang, Huijuan Li, Tong Yang, Sitong Guo, and Xiaoyu Chen. Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Frontiers Media S.A., 2022.

MLA (9th ed.) Citation

Yan Li, et al. Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Frontiers Media S.A., 2022.